Considering all the above facts, TNF-α and adiponectin seem to participate in the progression of NAFLD to advanced disease and HCC, a finding that renders both of them as potential diagnostic biomarkers and appealing therapeutic targets for the management of NAFLD-associated HCC. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.